Re: Initial D No One Sleep In Tokyo Mp3 Download
Lillia Iniguez
I'm looking at this sub and see crazy itinaries where people just arrive after a 12 hours+ flight, already get busy before getting their first meal, then think they can just go to bed, get 8 hours of sleep, wake up fresh like a daisy and the next day do 5 Tokyo areas in the morning, climb Fuji in the afternoon and party in Osaka the evening.
There's a good chance you barely slept in a dry and noisy airplane, have 8 or more hours of jetlag, won't be able to sleep well the first few nights and won't be in the mood to get packed in the subway and walk all day counting the minutes because there's still 8 things to do in your daily checklist before you're allowed to go to bed.
There's no shame to have a first day where you hang around the place you sleep, see a bit the neighborhood, check the local restaurants, buy a take away meal and enjoy it at home before you get an early sleep.
A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) in conjunction with the European Restless Legs Syndrome Study Group (EURLSSG) and the RLS Foundation (RLS-F) to develop evidence-based and consensus-based recommendations for the prevention and treatment of long-term pharmacologic treatment of dopaminergic-induced augmentation in restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Task Force made the following prevention and treatment recommendations: As a means to prevent augmentation, medications such as α2δ ligands may be considered for initial RLS/WED treatment; these drugs are effective and have little risk of augmentation. Alternatively, if dopaminergic drugs are elected as initial treatment, then the daily dose should be as low as possible and not exceed that recommended for RLS/WED treatment. However, the physician should be aware that even low dose dopaminergics can cause augmentation. Patients with low iron stores should be given appropriate iron supplementation. Daily treatment by either medication should start only when symptoms have a significant impact on quality of life in terms of frequency and severity; intermittent treatment might be considered in intermediate cases. Treatment of existing augmentation should be initiated, where possible, with the elimination/correction of extrinsic exacerbating factors (iron levels, antidepressants, antihistamines, etc.). In cases of mild augmentation, dopamine agonist therapy can be continued by dividing or advancing the dose, or increasing the dose if there are breakthrough night-time symptoms. Alternatively, the patient can be switched to an α2δ ligand or rotigotine. For severe augmentation the patient can be switched either to an α2δ ligand or rotigotine, noting that rotigotine may also produce augmentation at higher doses with long-term use. In more severe cases of augmentation an opioid may be considered, bypassing α2δ ligands and rotigotine.
The role of sleep is now recognized as an important component for success in athletic performance, and sleep is proposed to be one of the most effective recovery strategies available. Insufficient sleep is commonly reported among athletes while several factors have been put forward to explain why elite athletes might experience poor sleep. However, Paralympic athletes may be predisposed to a greater risk of poor sleep due to the associated complexities of some impairment types. In fact, clinical research has previously shown that individuals with disabilities have a higher prevalence of sleep disturbances when compared to their able-bodied counterparts. However, research and evidence-based practices regarding the sleep of elite Paralympic athletes are limited. Firstly, this narrative review aims to identify challenges associated with the Paralympic games to obtain optimal sleep. Secondly, identify the specific risk factors to sleep associated with particular impairment groups within the Paralympic population, and lastly to propose potential sleep-enhancing strategies that might be of relevance for Paralympic athletes. From this review, initial observations have identified that Paralympic athletes may have a heightened risk of sleep-related problems, and importantly highlighted the current lack of understanding within this population group. Furthermore, this review identified where further research is warranted to better understand how specific impairments impact sleep and, consequently, athletic performance. Additionally, this review highlighted that the forthcoming Tokyo games may offer a unique challenge for athletes trying to obtain optimal sleep, due to the anticipated thermal demands and the consequent irregular scheduling of events.
Study I was conducted in January and February of 2011, and study II was conducted in September and October of 2012. The Ota Memorial Sleep Center is a sleep clinic equipped with 9 PSG recording rooms, and all rooms were air conditioned throughout the year. Room temperatures of the sleep recording rooms logged 25.15 0.64C at 21:00 and 23.55 0.66C at 09:00 in January/February (study I) and 25.70 0.87C at 21:00 and 25.100.72C at 09:00 in September/October (study II).
A standard PSG consisting of EEGs from C3, C4, O1, O2, F3, and F4; EOG; submentalis EMG; chest electrocardiograms (ECG); and respiration curves derived by an oronasal thermistor and flowmeter (for an acclimation PSG night) was recorded using the Sandman system (Tyco Healthcare Japan, Inc. Tokyo, Japan) throughout the night. Sleep stages were scored every 30 seconds using the criteria described by Rechtschaffen and Kales [7]. Sleep onset was defined as the first epoch in which one of the sleep stages (Stage 1, 2, 3, 4, REM) were present after lights out. Final wakeup time was defined as the awakening time before lights on.
In addition to the PSG, the number of position changes during sleep, autonomic nerve activity (by monitoring ECG heart rate variability), core body temperature monitoring, and nighttime urinary GH levels were assessed. The rectal temperature was measured using a 401J thermistor probe (Nikkiso-Therm, Tokyo, Japan), and the data was captured with a NY Logger (N542R, Nikkiso) with a sampling rate of 1Hz. To measure the urinary GH levels secreted during the night, urine was collected in the morning when subjects woke up. In cases where subjects urinated during the night, all samples from during the night and morning were pooled for analysis. Urinary GH levels were measured using chemiluminescence immunoassay and corrected for creatinine [8]. VAS of sleep status (VAS-S), VAS performance (VAS-P), and the Stanford sleepiness scale (SSS) [9] were administered the following morning between 7:00 and 8:00 for subjective sleep evaluations (S1 Fig). Objective performance was evaluated with a psychomotor vigilance test (PVT) using a PVT task monitor (PVT192, CWE, Inc. Ardmore, PA, USA) [3, 4] (S1 Fig). Mean reaction time (RT), median RT, minimum RT, maximum RT, and lapses (RT > 500ms) were analyzed.
To evaluate the number of times subjects rolled over during sleep, a body position sensor (Pro-Tech, Woodinville, WA), which can distinguish five body positions (supine, prone, left lateral decubitus, right lateral decubitus, and sitting) was attached to the subjects [12]. The sleep position was recorded onto a polygraph in a coded format every 15 seconds, and it was monitored in real time by polysomnographic technologists that were attending the study. The number of times subjects changed body positions during sleep was calculated, and the time elapsed between the position change and subjects falling back to sleep was measured for each roll over episode. Changes in body position for less than 30 seconds were not considered for analysis.
(A) Changes in core body temperature during sleep with HR and LR in young adult males (study I). Larger and longer lasting decrease in core body temperature (CBT) was seen in the initial half of the sleep period with HR (p
In young subjects, subjective sleep status and performance (VAS) of the morning after the PSG study tended to be better with HR than with LR, though not at significant levels (Table 1). No significant differences in SSS and PVT were noted, while the mean number of PVT lapses (RT>500 ms) had non-significant tendency to be better with LR than with HR (Table 1). No significant change in urinary GH secretion during the night was observed (Table 1).
A series of experimental evidences suggested the functional importance of the first NREM sleep cycle for sleep [17, 18]. For example, the NREM sleep propensity, which is reflected in increased EEG delta power, is highest at the sleep onset, and the deepest NREM Sleep occurred at the first NREM cycle [18, 19]. NREM sleep propensity gradually declines toward the morning until subjects wake up [18, 19]. During the first NREM sleep cycle, GH, which stimulates growth, cell reproduction, cell regeneration, and metabolism, is secreted [20]. This GH secretion is mostly sleep-state dependent, and disruptions of the first cycle NREM sleep interferes with normal GH secretion [20]. Decrease in sympathetic nerve activity was also associated with deep sleep, and the decline of sympathetic nerve activity is largest at the first NREM sleep cycle [21]. It is also known that disruption of the first NREM sleep cycle disturbs the whole-night sleep wake cycle (see, [22]), and the first NREM sleep cycle is often bypassed in patients with psychiatric disorders (see, [17]). Therefore, even if sleep effects with HR are subtle, increases in EEG delta power in the initial half of the sleep likely merits the subjects.
Studies have also shown that temperature regulation before sleep and the initial phase of sleep is very import for sleep induction and sleep maintenance [23, 24]. Temperature is primarily regulated through two factors, namely heat production and heat loss [23]. The core body temperature is high during the daytime and low at night [24]. In contrast, distal skin temperature is low during the daytime and high at night [24]. The core body temperature is about 2C higher than the distal skin temperature [24]. Proximal skin temperature behaves similarly to core body temperature, but is lower than core body temperature [24].
aa06259810